Skip to content
2000
Volume 13, Issue 1
  • ISSN: 1871-5273
  • E-ISSN: 1996-3181

Abstract

Abnormal interactions of Zn2+ and Cu2+ with the amyloid β-peptide (Aβ) are proposed to play an important role in the neuropathogenesis of Alzheimer’s disease (AD). Metal chelators are potential therapeutic agents for AD because they could sequester metals ions from Aβ aggregates and reverse the aggregation. In this study, two nitrogencontaining ligands, TACN and BPA, have been investigated as possible metal chelators in the therapy of Alzheimer’s disease. The interactions between the chelators and Aβ40 aggregates are studied by turbidometry, thioflavin T (ThT) fluorescence spectroscopy, inductively coupled plasma mass spectrometry (ICP-MS), BCA protein assay, circular dichroism spectroscopy (CD), and atomic force microscopy (AFM). The results demonstrates that TACN and BPA are capable of both disrupting and preventing Zn2+ or Cu2+-induced Aβ40 aggregation. Moreover, they can also suppress the production of H2O2 induced by Cu-Aβ40, associated with toxic oxidative stress in AD.

Loading

Article metrics loading...

/content/journals/cnsnddt/10.2174/18715273113129990076
2014-02-01
2025-10-05
Loading full text...

Full text loading...

/content/journals/cnsnddt/10.2174/18715273113129990076
Loading

  • Article Type:
    Research Article
Keyword(s): Alzheimer’s disease; Amyloid β-peptide; Chelators; Metal
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test